Global Blood Testing Market Size and Overview

The Global Blood Testing Market was valued at USD 96.8 billion in 2024 and is projected to grow at a CAGR of 6.5% from 2025 to 2030, reaching an estimated USD 141.8 billion by 2030.

Blood testing plays a critical role in disease diagnosis, patient monitoring, preventive healthcare, and therapeutic management. It is one of the most widely performed diagnostic procedures worldwide and serves as the foundation for clinical decision-making across a range of healthcare settings. The market encompasses multiple test types, including glucose monitoring, lipid profiling, thyroid assessment, infectious disease detection, and hormone level evaluation. Rising awareness of early disease diagnosis, expanding diagnostic infrastructure, and increasing adoption of automated testing technologies are driving the growth of this sector. Preventive health checkups, chronic disease management programs, and the integration of advanced molecular technologies have further increased testing volumes globally. Additionally, growing investments in laboratory automation, development of next-generation testing devices, and emphasis on personalised healthcare approaches are expected to enhance market penetration over the forecast period.

Key Market Insights

Glucose tests and lipid panel tests account for more than 35% of the global test volume due to their widespread use in chronic disease management.

Automated testing methods make up over 60% of the market, driven by laboratory modernisation and rapid result delivery.

Reagents and kits represent more than 50% of revenue share, indicating their recurring demand in diagnostic workflows.

Nucleic acid testing and ELISA/CLIA remain dominant technologies for infectious disease and biomarker testing.

Hospitals and diagnostic laboratories together account for nearly 70% of the end-user base, reflecting centralised testing dominance.

North America holds over 35% of the global market share due to high testing rates and advanced infrastructure.

Rapid expansion of preventive health programs in the Asia-Pacific is expected to boost test volumes significantly over the forecast period.

In September 2025, startup Nutromics built a “lab-on-a-patch” wearable diagnostic device that uses DNA-based biosensors to continuously monitor multiple health markers, aiming to replace traditional blood draws in some diagnostic settings. 

Global Blood Testing Market Drivers

The rising global burden of chronic and infectious diseases is driving the market growth.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and thyroid dysfunction has fueled the need for regular blood testing worldwide. Glucose, lipid panel, and A1C tests are central to the management and monitoring of diabetes, which affects hundreds of millions globally. Cardiovascular disease remains one of the leading causes of death, and early detection through lipid panel and biomarker testing has become an essential public health strategy. In addition to chronic conditions, infectious diseases such as hepatitis, HIV, tuberculosis, and emerging viral infections require accurate and rapid testing for early intervention and containment. Blood testing remains one of the most efficient diagnostic methods for detecting these diseases at scale. The increasing emphasis on early screening programs, population-based diagnostics, and preventive healthcare further expands testing demand. Governments and healthcare systems worldwide are investing in large-scale screening initiatives, which directly increase testing volumes and expand laboratory capacity. Additionally, awareness among individuals regarding preventive checkups and wellness testing is higher than ever before, reinforcing market expansion.

Technological advancements and rapid automation of laboratories are driving the market growth.

Technological innovation plays a central role in transforming the blood testing landscape. Automated testing instruments and robotics have significantly reduced turnaround times and improved the accuracy and reliability of results. Modern analysers can process thousands of samples per hour, enabling laboratories to handle high testing volumes efficiently. Integration of AI-driven quality control systems and real-time monitoring ensures consistency and minimises manual errors. Molecular testing technologies, including NAT and NGS, have expanded the diagnostic capabilities of laboratories, enabling the detection of complex genetic and infectious conditions. Point-of-care solutions have also gained traction, allowing testing in clinics and home care settings, thereby increasing accessibility. Automation reduces the dependency on skilled labour, making testing scalable even in regions with limited healthcare personnel. Furthermore, interoperability between laboratory information systems and hospital records is improving operational efficiency. With continued investment in smart diagnostics and connected devices, testing workflows are expected to become faster, more cost-effective, and more patient-centric in the coming years.

Global Blood Testing Market Challenges and Restraints

High costs and limited access to advanced testing in low-resource settings are restricting the market growth.

Despite rapid technological advancements, the cost of implementing and maintaining advanced blood testing infrastructure remains a major challenge, particularly in developing and low-income countries. Automated analysers, molecular testing platforms, and high-quality reagents require significant capital investment, making it difficult for small laboratories and rural healthcare facilities to adopt these solutions. Additionally, the recurring costs associated with quality assurance, calibration, maintenance, and consumables contribute to the financial burden. Many regions also face shortages of trained laboratory personnel capable of operating sophisticated equipment and ensuring result accuracy. Limited reimbursement policies, out-of-pocket expenses, and lack of insurance coverage for preventive testing further restrict access in these markets. This economic divide creates unequal availability of testing, affecting early disease detection and population health management. While donor-funded programs and government initiatives attempt to bridge this gap, sustainable access remains a concern. Overcoming these costs and infrastructure barriers will be crucial to achieving equitable testing coverage globally.

Global Blood Testing Market Opportunities

The blood testing market presents substantial growth opportunities driven by the convergence of technological innovation, expanding healthcare infrastructure, and the increasing global focus on preventive health. One of the strongest opportunities lies in the further expansion of decentralised testing models. The rising adoption of point-of-care devices and at-home testing kits can bring diagnostic access closer to patients, especially in remote or underserved areas. The integration of wearable technologies and connected devices into healthcare ecosystems also offers prospects for continuous monitoring and personalised health management. Growing investments in molecular diagnostics and advanced biomarker discovery enable the development of more precise, rapid, and minimally invasive tests. Emerging economies are witnessing accelerated healthcare modernisation, creating new market entry and expansion pathways for global testing companies. Furthermore, the rise of digital health platforms, telemedicine integration, and AI-driven diagnostic support will enhance efficiency and patient engagement. Strategic collaborations between public health agencies, diagnostic manufacturers, and technology firms can help overcome infrastructure gaps and improve affordability. In addition, increased demand for personalised medicine and companion diagnostics is likely to stimulate new test development and drive innovation. As health systems prioritise early detection and value-based care, the demand for comprehensive blood testing solutions is expected to continue its upward trajectory through the forecast period.

BLOOD TESTING MARKET REPORT COVERAGE:

Global Blood Testing Market Segmentation

Global Blood Testing Market By Test Type

• Glucose tests
• Lipid panel tests
• A1C (glycated haemoglobin) tests
• Thyroid Stimulating Hormone (TSH) tests
• Prostate-Specific Antigen (PSA) tests
• Vitamin D tests
• CRP (C-reactive protein) tests
• ALT / AST (liver enzymes) tests
• BUN (blood urea nitrogen) tests
• Others

Glucose testing is the most dominant segment in the blood testing market due to the global prevalence of diabetes and the critical need for regular monitoring. Millions of patients rely on routine glucose checks to manage their condition effectively. This segment benefits from both laboratory-based and point-of-care testing solutions, making it accessible and scalable. Rising awareness of lifestyle-related health risks, government health initiatives, and the availability of affordable glucose testing devices are further contributing to its leadership in the market. Its integration with digital health platforms and home monitoring devices has increased its reach, making it one of the most widely performed tests worldwide.

Global Blood Testing Market By Method

• Manual testing methods
• Automated blood testing methods

Automated testing methods dominate the market due to their ability to deliver accurate and rapid results while handling large sample volumes. Laboratories are increasingly adopting automated analysers and robotics to improve operational efficiency and minimise human error. Automation supports standardisation, reduces turnaround time, and enhances throughput, which is essential in high-demand environments such as hospitals and diagnostic laboratories. As healthcare infrastructure modernises globally, automated solutions are expected to capture an even greater share, particularly in high-volume testing centres and urban healthcare settings.

Global Blood Testing Market By Components

• Reagents & kits
• Instruments/equipment
• Software & services

Reagents and kits represent the largest component segment because they are consumables and essential for each test performed, leading to recurring revenue streams. They form the backbone of most laboratory testing operations and are required regardless of the level of automation. Increased testing volumes, the expansion of disease screening programs, and frequent repeat testing in chronic conditions contribute to their dominant position in the market. Manufacturers are also introducing specialised reagents compatible with advanced analysers, strengthening this segment’s growth outlook.

Global Blood Testing Market By Technology

• Nucleic Acid Testing (NAT)
• ELISA, CLIA, etc. (serology tests)
• Next‐Generation Sequencing (NGS)
• Western blot, Rapid tests, Others

ELISA and CLIA-based serology tests dominate the technology segment due to their wide application in infectious disease screening, hormone level evaluation, and general health assessments. These methods are well-established, cost-effective, and suitable for both centralised and decentralised laboratory settings. Their proven reliability and compatibility with automation systems make them ideal for large-scale testing. Nucleic acid testing and NGS are expanding rapidly, but serology remains the most widely used testing technology worldwide.

Global Blood Testing Market By Disease

• Infection
• Anemia
• Leukemia/cancers
• Endocrine / metabolic disorders (e.g. diabetes, thyroid)

Endocrine and metabolic disorders are the most significant disease segment, primarily because of the global rise in diabetes and thyroid disorders. Regular glucose and hormone level monitoring is essential for disease management, prevention of complications, and improved quality of life. The segment benefits from strong reimbursement support, government screening programs, and accessible testing technologies. Growing lifestyle-related health concerns and awareness further reinforce the dominance of this disease category in the global testing landscape.

Global Blood Testing Market By End User

• Hospitals
• Diagnostic / Clinical Laboratories / Diagnostic Centres
• Clinics
• Research labs
• Blood banks/blood screening organisations

Hospitals represent the largest end-user segment due to their central role in patient diagnosis, treatment planning, and emergency care. They maintain high testing volumes through both routine screenings and specialised diagnostic procedures. Hospitals often operate advanced laboratory infrastructure with automated analysers and employ skilled laboratory professionals, ensuring efficient workflows. Their capacity to handle high patient inflows and complex cases secures their dominant share in the market.

Global Blood Testing Market Regional Segmentation

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

North America remains the dominant region in the blood testing market, accounting for more than one-third of the global share. The region benefits from highly advanced healthcare infrastructure, extensive insurance coverage, and widespread availability of diagnostic services. The United States, in particular, has high testing volumes driven by preventive care programs, chronic disease management initiatives, and frequent health checkups. Adoption of cutting-edge technologies, strong regulatory frameworks, and early integration of AI and automation give the region a competitive advantage. Furthermore, the presence of leading diagnostic companies, a robust distribution network, and continuous innovation in laboratory systems support sustained market leadership. Canada also contributes significantly through its universal healthcare approach, ensuring equitable access to testing. The region’s strong emphasis on wellness and early detection further reinforces its position as a global leader in blood testing services.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly accelerated demand for blood testing services globally. While initial disruptions in supply chains and elective procedures affected testing volumes in early 2020, the widespread implementation of COVID-related serological and molecular testing drove substantial market growth. Blood tests became essential for detecting infection, monitoring immune responses, and identifying inflammation markers associated with severe disease. Laboratories rapidly scaled up capacity, adopted automation, and implemented high-throughput systems to meet testing demands. In addition to COVID-specific tests, the pandemic increased public awareness of preventive healthcare, leading to a surge in routine health checkups after restrictions eased. Investments in diagnostic infrastructure expanded globally, improving accessibility and laboratory capabilities, particularly in developing countries. The experience also accelerated the adoption of digital tools, remote consultations, and point-of-care testing, which remain relevant post-pandemic. Overall, COVID-19 acted as a catalyst for modernisation, resilience, and growth in the blood testing market, with many innovations continuing to shape the industry in the years ahead.

Latest Trends/Developments

The blood testing market is experiencing several transformative trends. The rise of point-of-care testing and home-based diagnostic solutions is increasing patient access and convenience, enabling faster diagnosis and improved disease monitoring. Wearable devices integrated with biosensors are enabling real-time health insights, enhancing preventive healthcare strategies. Automation and digitalisation remain central trends, with AI-powered platforms improving diagnostic accuracy, reducing errors, and streamlining workflows. Advanced molecular testing technologies like NGS and NAT are expanding the scope of testing to include genetic profiling and early cancer detection. Industry players are focusing on developing multiplexed assays capable of detecting multiple biomarkers from a single sample, improving efficiency and cost-effectiveness. In addition, sustainability considerations are leading to the introduction of eco-friendly consumables and energy-efficient laboratory systems. Strategic partnerships between diagnostic companies, tech firms, and healthcare providers are accelerating product innovation and market expansion. These developments collectively signal a shift toward personalised, accessible, and efficient testing ecosystems, setting the stage for future market growth.

Global Blood Testing Market Key Players

1. Abbott Laboratories
2. Roche Diagnostics
3. Siemens Healthineers
4. Bio-Rad Laboratories
5. Danaher Corporation
6. Thermo Fisher Scientific
7. Quest Diagnostics
8. Beckman Coulter
9. Ortho Clinical Diagnostics
10. Sysmex Corporation

Market News

In February, 2025, Hims & Hers Health shares hit a record high following its acquisition of Trybe Labs, enabling the company to introduce at-home blood testing services for markers like cholesterol, hormone levels, thyroid, etc.

In April, 2025, Labcorp announced its Q1 2025 results, introduced new blood tests, including a liquid biopsy test for cancer and a pTau-217/Beta Amyloid 42 Ratio test for Alzheimer’s disease diagnosis, reinforcing its strategy to expand in oncology, women’s health, autoimmune disease, and neurology.